Lord Jenny, Oquendo Carolina J, Wai Htoo A, Holloway John G, Martin-Geary Alexandra, Blakes Alexander J M, Arciero Elena, Domcke Silvia, Childs Anne-Marie, Low Karen, Rankin Julia, Baralle Diana, Martin Hilary C, Whiffin Nicola
School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Sheffield Institute for Translational Neuroscience (SITraN), The University of Sheffield, Sheffield, United Kingdom.
School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Genet Med. 2024 Dec;26(12):101249. doi: 10.1016/j.gim.2024.101249. Epub 2024 Sep 3.
Identifying pathogenic noncoding variants is challenging. A single protein-altering variant is often identified in a recessive gene in individuals with developmental disorders (DD), but the prevalence of pathogenic noncoding "second hits" in trans with these is unknown.
In 4073 genetically undiagnosed rare-disease trio probands from the 100,000 Genomes project, we identified rare heterozygous protein-altering variants in recessive DD-associated genes. We identified rare noncoding variants on the other haplotype in introns, untranslated regions, promoters, and candidate enhancer regions. We clinically evaluated the top candidates for phenotypic fit and performed functional testing where possible.
We identified 3761 rare heterozygous loss-of-function or ClinVar pathogenic variants in recessive DD-associated genes in 2430 probands. For 1366 (36.3%) of these, we identified at least 1 rare noncoding variant in trans. Bioinformatic filtering and clinical review, revealed 7 to be a good clinical fit. After detailed characterization, we identified likely diagnoses for 3 probands (in GAA, NPHP3, and PKHD1) and candidate diagnoses in a further 3 (PAH, LAMA2, and IGHMBP2).
We developed a systematic approach to uncover new diagnoses involving compound heterozygous coding/noncoding variants and conclude that this mechanism is likely to be a rare cause of DDs.
识别致病性非编码变异具有挑战性。在发育障碍(DD)个体的隐性基因中,通常会鉴定出单个蛋白质改变变异,但与之处于反式的致病性非编码“二次打击”的患病率尚不清楚。
在来自“十万基因组计划”的4073名未经基因诊断的罕见病三联体先证者中,我们在隐性DD相关基因中鉴定出罕见的杂合蛋白质改变变异。我们在另一个单倍型的内含子、非翻译区、启动子和候选增强子区域鉴定出罕见的非编码变异。我们对最有可能符合表型的候选者进行临床评估,并在可能的情况下进行功能测试。
我们在2430名先证者的隐性DD相关基因中鉴定出3761个罕见的杂合功能丧失或ClinVar致病性变异。其中1366个(36.3%),我们鉴定出至少1个反式的罕见非编码变异。生物信息学筛选和临床评估显示,7个变异在临床上高度符合。经过详细表征,我们确定了3名先证者(分别涉及GAA、NPHP3和PKHD1基因)的可能诊断,并在另外3名先证者(PAH、LAMA2和IGHMBP2基因)中确定了候选诊断。
我们开发了一种系统方法来发现涉及复合杂合编码/非编码变异的新诊断,并得出结论,这种机制可能是DD的罕见病因。